Company news

Share this article:
Thomson Scientific, part of The Thomson Corporation, launched its Citation Impact Forum, an online forum promoting scholarly discussion about all facets of citation-based research evaluation. The Citation Impact Forum will feature interviews with and commentary from industry leaders - bibliometricians, researchers and publishers - about scholarly evaluation.  By becoming a registered member of the forum, users have the added ability to join invitation only forums where they can participate in discussions by sharing their own thoughts with other members.  Registered members can also recommend future forum discussion topics. Thomson Scientific will also use the Forum to address - or to clarify -- inaccuracies and common misinterpretations circulating among the scientific community, printed in journals, blogs and other forums.  Thomson Scientific's Citation Impact Forum, can be found by visiting: scientific.thomson.com/citationimpactforum/.

Bedford Laboratories, a division of Ben Venue Laboratories Inc., announced the acquisition of Cafcit (caffeine citrate) Injection and Cafcit (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. Cafcit (caffeine citrate) is indicated for the short-term treatment of apnea in premature infants between 28 and <33 weeks gestational age. Ben Venue Laboratories is a subsidiary of Boehringer Ingelheim.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.